A Randomized, Double-blind, Vehicle-Controlled Phase 2a Study Evaluating Once Daily Roflumilast Foam 0.3% in Patients With Moderate to Severe Seborrheic Dermatitis. (2021). SKIN The Journal of Cutaneous Medicine, 5(6), s94. https://doi.org/10.25251/skin.5.supp.94